• About us
• Contact

Advertisement

Person › Details

Pascal Neuville (Domain Therapeutics S.A.)

Neuville, Pascal (Domain Therapeutics 200812c– CEO)

 

	Organisation	Domain Therapeutics S.A.
	Group	Domain Therapeutics (Group)
	Product	GPCR inhibitor
	Product 2	CNS drug (neurological drug)

Record changed: 2022-05-14

Advertisement

More documents for Pascal Neuville

• [1] Domain Therapeutics S.A.. (5/12/22). "Press Release: Domain Therapeutics Raises $42m Series A Financing to Accelerate Clinical Development of Its Best-in-Class and First-in-Class Immuno-oncology Programs". Strasbourg & Montréal, ON....
• [2] Domain Therapeutics S.A.. (1/13/20). "Press Release: Domain Therapeutics Secures €6 Million ($6.7M) Debt Financing". Strasbourg....
• [3] Domain Therapeutics S.A.. (9/11/19). "Press Release: Domain Therapeutics Invests in Ermium Therapeutics to Develop First-in-class CXCR4 Candidate for Autoimmune Diseases". Strasbourg....
• [4] Ermium Therapeutics S.A.S.. (9/11/19). "Press Release: Ermium Therapeutics Completes Series A Funding of €6.3 Million to Develop Breakthrough Auto-immune Therapeutics". Paris....
• [5] Domain Therapeutics S.A.. (5/28/19). "Press Release: European Venture Capital Firm Seventure Partners Renews Its Support to Domain Therapeutics and Invests €3.5M ($3.9M) to Prepare the Next Growth Phase". Strasbourg....
• [6] Domain Therapeutics S.A.. (12/4/18). "Press Release: Domain Therapeutics Signs a Multi-target Research Collaboration and License Agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders". Strasbour...
• [7] Domain Therapeutics S.A.. (4/25/17). "Press Release: Pfizer Inc. and Domain Therapeutics Enter into a Collaboration Agreement on bioSensAll". Strasbourg & Montréal, ON....
• [8] Merck KGaA. (1/23/17). "Press Release: Merck Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology [Not intended for UK- or US-based media]". Darmstadt....
• [9] Domain Therapeutics S.A.. (1/23/17). "Press Release: Domain Therapeutics and Merck Enter into a License and Collaboration Agreement for Development of Adenosine Receptor Antagonists in Immuno-oncology". Strasbourg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.